ArticlePloS one2017
Searching for new strategies against biofilm infections: Colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus single- and double-species biofilms.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Duloxetine repositioning: Investigation of antifungal and antibiofilm activity against fluconazole-sensitive and resistant Candida Spp. strains.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Antifungal Activity and Possible Mechanism of Action of the Zn (II) Complex With a Schiff Base Against Fluconazole-Resistant Strains of Candida spp. and Cryptococcus neoformans.Chemistry & biodiversity · 2026Article
- Synthesis and antibacterial activity study of anti-biofilm agents based on American oyster defensin analog A4.RSC advances · 2026Article
- Recombinant AMPs (Epinecidin-1 and its Variants): A New Hope against Invasive Fungal Infections against Candida spp. and Aspergillus flavus.Current microbiology · 2026Article
- Enhanced antibacterial activity of antimicrobial peptide-antibiotic combinations against multidrug-resistant bacteria.FEMS microbes · 2026Review
- Antibacterial Evaluation of Tricyclic Antidepressants AgainstPathogens (Basel, Switzerland) · 2025Article
- DJK-5, an anti-biofilm peptide, increases Staphylococcus aureus sensitivity to colistin killing in co-biofilms with Pseudomonas aeruginosa.NPJ biofilms and microbiomes · 2025Article
- Biofilm and surface-motility profiles under polymyxin B stress in multidrug-resistant KAPE pathogens isolated from Ghanaian hospital ICUs.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Analysis of the anti-Candida activity of tricyclic antidepressants in association with amphotericin B and their antifungal mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Antifungal activity of tannic acid against Candida spp. and its mechanism of action.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Polylactic acid-based dressing with oxygen generation and enzyme-like activity for accelerating both light-driven biofilm elimination and wound healing.Burns & trauma · 2024Article
- Anticandidal activity ofFuture microbiology · 2024Article
- Novel Antibacterial Agents SAAP-148 and Halicin Combat Gram-Negative Bacteria Colonizing Catheters.Antibiotics (Basel, Switzerland) · 2023Article
- Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producingiScience · 2023Article
- Synthetic peptides that form nanostructured micelles have potent antibiotic and antibiofilm activity against polymicrobial infections.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Anti-Frontiers in microbiology · 2023Review
- 'Targeting' the search: An upgraded structural and functional repository of antimicrobial peptides for biofilm studies (B-AMP v2.0) with a focus on biofilm protein targets.Frontiers in cellular and infection microbiology · 2022Article
- Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review.Frontiers in pharmacology · 2022Review
- Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial research is being pressured to look for more effective therapeutics for the ever-growing antibiotic-resistant infections, and antimicrobial peptides (AMP) and antimicrobial combinations are promising solutions. This work evaluates colistin-AMP combinations against two major pathogens, Pseudomonas aeruginosa and Staphylococcus aureus, encompassing non- and resistant strains. Colistin (CST) combined with the AMP temporin A (TEMP-A), citropin 1.1 (CIT-1.1) and tachyplesin I linear analogue (TP-I-L) was tested against planktonic, single- and double-species biofilm cultures. Overall synergy for planktonic P. aeruginosa and synergy/additiveness for planktonic S. aureus were observed. Biofilm growth prevention was achieved with synergy and additiveness. Pre-established 24 h-old biofilms were harder to eradicate, especially for S. aureus and double-species biofilms; still, some synergy and addictiveness was observed for higher concentrations, including for the biofilms of resistant strains. Different treatment times and growth media did not greatly influence AMP activity. CST revealed low toxicity compared with the other AMP but its combinations were toxic for high concentrations. Overall, combinations reduced effective AMP concentrations, mainly in prevention scenarios. Improvement of effectiveness and toxicity of therapeutic strategies will be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.